Assessing Sarepta Therapeutics: Insights From 12 Financial Analysts

Sarepta Therapeutics, Inc. +2.58% Pre

Sarepta Therapeutics, Inc.

SRPT

116.25

122.00

+2.58%

+4.95% Pre

In the preceding three months, 12 analysts have released ratings for Sarepta Therapeutics (NASDAQ:SRPT), presenting a wide array of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 5 6 1 0 0
Last 30D 0 1 0 0 0
1M Ago 2 2 0 0 0
2M Ago 2 0 0 0 0
3M Ago 1 3 1 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $148.92, a high estimate of $224.00, and a low estimate of $80.00. This current average has increased by 32.26% from the previous average price target of $112.60.

price target chart

Breaking Down Analyst Ratings: A Detailed Examination

The standing of Sarepta Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Andreas Argyrides Wedbush Maintains Outperform $224.00 -
Gil Blum Needham Maintains Buy $140.00 -
Brian Abrahams RBC Capital Lowers Outperform $151.00 $155.00
Gil Blum Needham Raises Buy $140.00 $93.00
Andreas Argyrides Wedbush Maintains Outperform $224.00 -
David Hoang Citigroup Announces Buy $113.00 -
Neena Bitritto-Garg Deutsche Bank Announces Buy $109.00 -
Brian Abrahams RBC Capital Maintains Outperform $148.00 -
Andreas Argyrides Wedbush Announces Outperform $224.00 -
Gena Wang Barclays Lowers Overweight $141.00 $193.00
Kristen Kluska Cantor Fitzgerald Raises Neutral $80.00 $40.00
Gil Blum Needham Raises Buy $93.00 $82.00

Key Insights:

  • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
  • Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.
  • Price Targets: Delving into movements, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.

To gain a panoramic view of Sarepta Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Sarepta Therapeutics analyst ratings.

Get to Know Sarepta Therapeutics Better

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics's Financial Performance

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Over the 3 months period, Sarepta Therapeutics showcased positive performance, achieving a revenue growth rate of 44.1% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Sarepta Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -12.34%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Sarepta Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.44%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Sarepta Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.31%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Sarepta Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.79, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

What Are Analyst Ratings?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via